Company Monitoring Page for Zogenix

latest headlines for company on cafepharma

Controversial opioid Zohydro ER pulled from the market
Endpoints
Thu, 02/3/22 - 12:00 am
Tags:
UCB Pharma, epilepsy, Zogenix, Zohydro ER
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
BioPharma Dive
Wed, 01/19/22 - 11:12 am
Tags:
UCB Pharma, Zogenix, Fintepla, Dravet syndrome
Catalyst, Zogenix, Rigel and Pfizer kick off pharma's July price hikes: report
Fierce Pharma
Thu, 07/1/21 - 10:22 pm
Tags:
drug pricing, Pfizer, Zogenix, Rigel Pharmaceuticals, Catalyst Pharmaceuticals
Fortunes diverge for solo drug launchers
EP Vantage
Tue, 05/11/21 - 11:01 am
Tags:
drug launches, Intra-Cellular Therapies, Biocryst, Horizon Therapeutics, Karyopharm Therapeutics, Blueprint Medicines, Zogenix, Esperion, Epizyme, Aurinia Pharmaceuticals, Global Blood Therapeutics
FDA Approves Zogenix's Drug for Rare Childhood Epilepsy
NY Times, NY
Fri, 06/26/20 - 09:46 am
Tags:
FDA, Zogenix, epilepsy, Dravet syndrome
FDA pushes back decision on Zogenix epilepsy drug
BioPharma Dive
Thu, 02/27/20 - 11:41 pm
Tags:
Zogenix, epilepsy, Fintepla, FDA, Dravet syndrome
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Wed, 02/26/20 - 10:26 am
Tags:
Bristol-Myers Squibb, ozaminod, MS, multiple sclerosis, Zogenix, Fintepla, FDA
Zogenix's Positive Clinical Trial Wasn't Positive Enough
Motley Fool
Sun, 02/9/20 - 04:08 pm
Tags:
Zogenix, epilepsy, Lennox-Gastaut Syndrome, clinical trials, Fintepla, GW Pharma, Epidiolex
Zogenix hands GW a win
EP Vantage
Fri, 02/7/20 - 10:32 am
Tags:
Lennox-Gastaut Syndrome, clinical trials, Fintepla, Zogenix, GW Pharma
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
EP Vantage
Fri, 01/24/20 - 10:50 am
Tags:
Genmab, tisotumab vedotin, cervical cancer, Zogenix, Fintepla, Lennox-Gastaut Syndrome
New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug
BioSpace
Fri, 10/25/19 - 10:42 pm
Tags:
Zogenix, Fintepla, Dravet syndrome, epilepsy
Why Shares of Drugmaker Zogenix Dropped 11.4% in August
Motley Fool
Fri, 09/6/19 - 08:36 pm
Tags:
Zogenix, Fintepla, Dravet syndrome
From $30M launch round to $400M buyout deal — with $250M upfront — in 10 short months
Endpoints
Mon, 08/26/19 - 09:58 am
Tags:
Modis, M&A, Zogenix, F-Prime
Zogenix Prepares for Second Shot at Seizure Drug Submission
BioSpace
Tue, 07/30/19 - 04:23 pm
Tags:
Zogenix, anti-seizure, FDA, Fintepla
Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike
Endpoints
Thu, 06/27/19 - 11:42 am
Tags:
Zogenix, FDA, Dravet syndrome, Fintepla
FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work
Endpoints
Mon, 04/8/19 - 11:21 pm
Tags:
Zogenix, Dravet syndrome, FDA, refuse to file letters
These Epilepsy Drugmakers Are About to Brawl
Motley Fool
Thu, 07/19/18 - 11:30 pm
Tags:
epilepsy, Zogenix, ZX008, GW Pharma, Epidiolex
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Xconomy
Thu, 07/12/18 - 09:59 am
Tags:
Dravet syndrome, clinical trials, Zogenix, ZX008, FenPhen, GW Pharma, Epidiolex
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Tue, 07/3/18 - 11:04 am
Tags:
Spark Therapeutics, Zogenix, Progenics Pharmaceuticals, SPK-8011, ZX008, Azedra, FDA
Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’
Endpoints
Tue, 02/6/18 - 09:24 am
Tags:
Zogenix, FDA, epilepsy, Dravet syndrome, ZX008, breakthrough therapies

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.